BioCentury
ARTICLE | Finance

Weill Cornell spinout Lexeo raises $85M series A to develop clinical gene therapy programs

January 7, 2021 11:44 PM UTC

With a portfolio of three gene therapy programs from Weill Cornell, two of which have already reached the clinic, start-up Lexeo has drawn $85 million in series A funding from a syndicate led by Longitude Capital and Omega Funds.

Lexeo Therapeutics’ LX1004 for CLN2 Batten disease has already completed a Phase I/II trial, and its LX1001 for APOE4-associated Alzheimer’s disease is in Phase I testing. A Phase I trial is to start this year of LX2006 to treat cardiomyopathy associated with Friedreich's ataxia...